Printer Friendly

PHARMOS CORPORATION CONTINUING PROGRESS IN OPHTHALMIC RESEARCH

 SARASOTA, Fla., May 3 /PRNewswire/ -- At this week's Association for Research in Vision and Ophthalmology (ARVO) Conference in Sarasota, Pharmos Corporation (NASDAQ Small Cap: PARS) scientists are presenting three papers based on Pharmos' novel pharmaceutical products based on innovative drug delivery technologies targeting the eye, the company announced today.
 The first of these describes the results of Pharmos' new pharmacological approach to glaucoma using a proprietary compound, HU-211. HU-211 demonstrates neuroprotective activity for the optic nerve as well as IOP (IntraOcular Pressure) reducing activity. The second study presents data on Pharmos' new formulation of an existing glaucoma therapy. The third of these presentations addresses the value of the company's drug delivery technology in conjunction with other ocular therapies.
 Included in the research being presented are the results of human clinical trials using Pharmos' new formulation of an established glaucoma therapy. The data show reduction of intraocular pressure to desired levels with a single dose of the agent. These results confirm the value of the company's drug delivery technology in reducing the side effects while increasing efficacy.
 The improved performance of a number of ocular drugs, when formulated with SME (SubMicron Emulsion) technology, was shown in a third study. The results of several efficacy measures are presented at the meeting. "The acceptance of these papers validates our belief that drugs utilizing the SME delivery technology are more readily absorbed, thus producing more efficacious drugs with fewer side effects," said Haim Aviv, Ph.D., chairman and chief executive officer of Pharmos. "The beauty of this technology is that it can be used in a variety of existing ophthalmic drugs, rendering them safer and more comfortable to the patient."
 In addition to research being presented at ARVO, Pharmos announced today the successful completion of Phase I clinical trials on Adaprolol Maleate, a novel eye-active beta blocker for glaucoma with a favorable side effect profile, including no systemic activity and an absence of cardiovascular and pulmonary side effects normally associated with beta-blockers.
 Pharmos Corporation is engaged in the development of novel pharmaceuticals based on innovative drug delivery technologies targeting diseases of the eye, principally glaucoma and ocular inflammation, and the brain, principally stroke and head trauma.
 -0- 5/3/93
 /CONTACT: Stephen R. Streber, president and COO of Pharmos, 212-838-0087; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, or Donald C. Weinberger of Strategic Growth International, 212-826-9622, both for Pharmos/
 (PARS)


CO: Pharmos Corporation ST: New York, Florida IN: MTC SU:

TS-GK -- NY071 -- 3861 05/03/93 13:55 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 3, 1993
Words:419
Previous Article:NAVY, RAYTHEON CONDUCT SUCCESSFUL AEDIS-ER MISSILE TEST FLIGHT
Next Article:PHARMOS CORPORATION PRESENTS FIRST STUDIES ON NOVEL ANTIGLAUCOMA NEUROPROTECTIVE AGENT
Topics:


Related Articles
PHARMOS COMPLETES $65 MILLION MERGER OF PHARMATEC; TO FOCUS EXPANDED TECHNOLOGY BASE ON DEVELOPMENT/COMMERCIALIZATION OF DRUGS FOR EYES,BRAIN
PHARMOS CORPORATION PRESENTS FIRST STUDIES ON NOVEL ANTIGLAUCOMA NEUROPROTECTIVE AGENT
PHARMOS CORPORATION ADDRESSES KEY COMPLIANCE ISSUES WITH SME TECHNOLOGY
PHARMOS' TREATMENT SHOWS EFFICACY IN GIANT PAPILLARY CONJUNCTIVITIS; PHARMOS REPORTS DATA FROM CLINICAL STUDIES
PHARMOS ANNOUNCES MARKETING/PRODUCTION ARRANGEMENT WITH BAUSCH & LOMB FOR NOVEL OPHTHALMIC TREATMENT
PHARMOS ANNOUNCES THE SUCCESSFUL COMPLETION OF PHASE III CLINICAL TRIALS FOR LOTEMAX
PHARMOS ANNOUNCES SUBMISSION OF CHEMISTRY, MANUFACTURING AND CONTROL SECTION OF LOTEMAX NEW DRUG APPLICATION (NDA) TO FDA
PHARMOS ANNOUNCES SUBMISSION OF CHEMISTRY, MANUFACTURING AND CONTROL SECTION OF LOTEMAX NEW DRUG APPLICATION (NDA) TO FDA
Pharmos Initiates Phase II Study to Evaluate Dexanabinol in Traumatic Head Injury Patients
Pharmos Completes $6 Million Private Placement

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters